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Abstract
 
PML–RARA
 
 was proposed to initiate acute promyelocytic leukemia (APL) through PML–
RARA homodimer–triggered repression. Here, we examined the nature of the PML–RARA
protein complex and of its DNA targets in APL cells. Using a selection/amplification approach,
we demonstrate that PML–RARA targets consist of two AGGTCA elements in an astonishing
variety of orientations and spacings, pointing to highly relaxed structural constrains for DNA
binding and identifying a major gain of function of this oncogene. PML–RARA-specific re-
sponse elements were identified, which all conveyed a major transcriptional response to RA
only in APL cells. In these cells, we demonstrate that PML–RARA oligomers are complexed
to RXR. Directly probing PML–RARA function in APL cells, we found that the differentiation
enhancer cyclic AMP (cAMP) boosted transcriptional activation by RA. cAMP also reversed
the normal silencing (subordination) of the transactivating function of RXR when bound to
RARA or PML–RARA, demonstrating that the alternate rexinoid/cAMP-triggered APL
differentiation pathway also activates PML–RARA targets. Finally, cAMP restored both RA-
triggered differentiation and PML–RARA transcriptional activation in mutant RA-resistant
APL cells. Collectively, our findings directly demonstrate that APL cell differentiation parallels
transcriptional activation through PML–RARA-RXR oligomers and that those are functionally
targeted by cAMP, identifying this agent as another oncogene-targeted therapy.
Key words: therapy • leukemia • selex • transcription • oncogene
 
Introduction
 
Acute promyelocytic leukemia (APL) is triggered by a
chromosomal translocation that yields expression of the
 
PML–RARA
 
 oncogene, a fusion protein between a transcrip-
tion factor, the retinoic receptor (RARA), and an organizer of
nuclear domains involved in apoptosis, PML. RARA belongs
to the nuclear receptor family and binds DNA as a het-
erodimer with the nuclear receptor RXR. Response elements
consist of direct repeats (DRs) of a (A/G)G(G/T)TCA
consensus with spacings of 2 or 5, whereas RXR homodimers
bind DR1 and DR6 elements (1). RXR-specific agonists
(rexinoids) fail to activate transcription from RAR–RXR
complexes, a process referred to as RXR subordination (2).
This results from a steric hindrance of RARA-bound core-
pressors that impede the binding of coactivators onto RXR
(3). Numerous observations indicate that PML–RARA is a
potent repressor, which could turn down the expression of
RA target genes critical to myeloid differentiation (4).
PML harbors a strong dimerization domain that allows for-
mation of PML–RARA homodimers, which bind DNA
independently of RXR (5, 6). PML–RARA homodimers
bind corepressors more tightly than RAR–RXR het-
erodimers, which could account for enhanced repression
(7–9). It was also proposed that the binding of two core-
pressor molecules, rather than one, may contribute to
PML–RARA-triggered repression (10, 11).
APL is a target for differentiation therapy because several
agents can induce in vivo differentiation of the leukemic
cells, yielding clinical remissions (12). At least two of these
agents, retinoic acid or arsenic directly targets PML–RARA
through each of its constitutive moieties (13–15). Targeting
 
The online version of this article contains supplemental material.
Address correspondence to Hugues de Thé, CNRS UPR9051, Hôpital
St. Louis, Laboratoire associé N
 
  
 
11, 1, Av. C. Vellefaux, 75475 Paris,
Cedex 10, France. Phone: 33-1-53-72-21-91; Fax: 33-1-53-72-21-90;
email: dethe@chu-st-louis.fr
 
Abbreviations used in this paper:
 
 APL, acute promyelocytic leukemia; DR,
direct repeat; EMSA, electrophoretic mobility shift assay. 
cAMP/Rexinoid Transactivation on PML–RARA-specific Elements
 
1164
by these two agents results in the degradation of the PML–
RARA oncogene, yet, the role of degradation versus tran-
scriptional activation has been unclear, in part because RA
can simultaneously activate RAR and PML–RARA. Simi-
larly, cAMP is well known to synergize with RA to trigger
differentiation in several cell types including APL cells (16,
17). In the case of F9 embryonal carcinoma cells, the molec-
ular basis of the RA/cAMP cross-talk for parietal endoderm
differentiation was shown to be cAMP-triggered RARA
phosphorylation, although cAMP did not enhance expres-
sion of the RA target genes tested (18). Finally, previous
studies have suggested the existence, in APL cells, of an al-
ternate RXR/cAMP differentiation pathway, independent
from PML–RARA (19, 20). This pathway could be active
in non-APL leukemias and extend the concept of differenti-
ation therapy to other hematological malignancies (21).
In this study, we have performed an unbiased selection
for DNA sequences that bind to PML–RARA homo-
dimers and identified binding sites consisting of two copies
of an AGGTCA core in a wide variety of spatial arrange-
ments, demonstrating that PML–RARA deregulates a much
wider network of target genes than previously thought. All
of these sequences could confer retinoic acid response,
some of them exclusively, in PML–RARA-expressing
cells. We show that in APL cells PML–RARA homo-
dimers are RXR bound. A dramatic synergy between RA,
RAR-specific agonists, as well as RXR-specific agonists
and cAMP was identified at the transcription activation
level, which results, at least in part, from cAMP-triggered
RXR desubordination. Hence, in APL, a PML–RARA-
RXR oligomer binds an extended repertoire of response
elements and is functionally targeted by the differentiation
inducer cAMP.
 
Materials and Methods
 
Preparation of the Cell Extracts.
 
Cos-7 cells transiently trans-
fected with pSG5-PML–RARA were lysed in ice for 30 min in
the lysis buffer (50 mM Tris, pH 8.0, 0.6% [vol/vol] Igepal CA-
630 [Sigma-Aldrich], 480 mM NaCl, 10% [vol/vol] glycerol, 0.1
mM EDTA, 1 mM DTT, 1.5 mM sodium vanadate, 0.4 mM
PMSF, 3 
 
 
 
g/ml aprotinin, 1 
 
 
 
g/ml pepstatin, 1 
 
 
 
g/ml leupep-
tin). The centrifugation supernatant was stored at 
 
 
 
80
 
 
 
C.
 
Selection and Amplification of Binding Sequences.
 
The amplifica-
tion and binding selection method was modified as previously
described (22), using an oligonucleotide pool of randomized sin-
gle-stranded oligonucleotide template 5
 
 
 
-CACATTCCTTCG-
GCGGATCCAGTCG-(N)
 
25
 
-TAGGCTCTAGAATTCCAT-
GCGCAGC. Double-stranded oligonucleotides were generated
by annealing the 5
 
  
 
primer (5
 
 
 
-CACATTCCTTCGGCGGA-
TCCAGTCG) to the single-stranded template and extending
with Klenow fragment of DNA polymerase I. The double-
stranded templates were end labeled with 
 
 
 
P
 
32
 
-ATP. End-labeled
templates were mixed with extract of PML–RARA-transfected
cells in the binding buffer (25 mM Tris, pH 8.0, 0.15 mM DTT,
140 mM NaCl, 0.075% [vol/vol] Igepal CA-630 [Sigma-
Aldrich], 10% [vol/vol] glycerol, 0.2 mg/ml BSA). DNA–pro-
tein complexes were separated on a 3.75% polyacrylamide gel
buffered with 45 mM Tris, 45 mM borate, and 0.1 mM EDTA at
4
 
 
 
C for 2 h. An oligonucleotide probe of the same length as a
randomized matrix (75 bp) containing the RAREB (23) served as
a marker for migration of the two PML–RARA-DNA com-
plexes. The gel slices corresponding to the position of the posi-
tive controls DIM and OLI (see Fig. 1 A) were excised. The
eluted selected pool was PCR amplified with 5
 
  
 
(see above) and
3
 
  
 
primer (5
 
 
 
-GCTGCGCATGGAATTCTAGAGCCTA), gel
purified, and labeled as described above for subsequent rounds of
selection. For each subsequent round, we decreased a quantity of
template twice or thrice, starting from 400 pmol DNA. The con-
centration of the cell extract was chosen from a pilot experiment
where 1 pmol of the nonlabeled template and labeled RAREB
were mixed with various amounts of the extract. The concentra-
tion of the extract able to shift 7–14% of the RAREB was used
for the preparative selection step. After five (for band OLI) and
six (for band DIM) rounds, the selected oligonucleotides were
subcloned into the pGEM-7Zf(
 
 
 
) cloning vector and 174 of
them were sequenced.
 
Oligonucleotides.
 
Oligonucleotides representing the DRs were
5
 
 
 
-AATCGTCGACACCAAAGGTCA -spacer- AGGTCAC-
GACTCGAGCATT, where the spacers were as follows: Dr1 A,
Dr2 AA, Dr3 AAA, Dr4 ACAA, Dr5 ACGAA, Dr6 ACGGAA,
Dr8 ACGGCGAA, Dr10 ACGGAACGAA, Dr12 ACGGAT-
TACGAA, Dr14 ACGGATCTTACGAA, Dr16 ACGGA-
TCGATTACGAA, Dr20 ACGGATCGTAGAATTACGAA.
The palindromes were prepared from the sequences IR0 5
 
 
 
-
AATCGTCGACCCAAAGGTCATGACCTTTGTCTCGAG-
CATT and ER8 5
 
 
 
-AATCGTCGACCACGTGACCTTTA-
CCCAAAGGTCACGATCTCGAGCATT. As negative con-
trols, we used the sequence DR5 carrying base substitutions in
one or both hexamers.
 
Electrophoretic Mobility Shift Assay (EMSA).
 
For EMSAs, the
whole cell extract of the Cos cells transiently transfected with
pSG5 expression vector(s) containing PML-RAR. RXR and
RAR genes were presented to the variety of the consensus PML-
RARA–binding sequences. PCR-constructed DNA probes were
gel purified and labeled as described above and mixed with cellu-
lar extract in the binding buffer as above with 0.02 
 
 
 
g/
 
 
 
l
poly(dI-dC) at room temperature. DNA–protein complexes and
free DNA were separated on a 3.75% polyacrylamide gel.
 
Cell Culture, Transient Transfections, and Reporter Gene Assays.
 
Double-stranded oligonucleotides, described above for EMSA,
were digested with XhoI/SalI and ligated into SalI-digested
pTK-Luc (23). All plasmids were selected in which a single copy
of the binding site was oriented in the same direction. For pTK-
Dr constructs, the binding sites were all oriented such that the
TGACCT sequence was followed by the promoter.
Cos cells were transiently transfected with 0.24 
 
 
 
g pTK-Luc
reporter plasmids, 0.04 
 
 
 
g pRLtk (Promega), and 0.03 
 
 
 
g ex-
pression vector per 4 cm
 
2 
 
wells. Cells were grown in medium
containing 10% FBS for 2 h and then the media was changed to
5% charcoal resin-stripped (super-stripped) FBS and either 1 
 
 
 
M
RA (Sigma-Aldrich) or ethanol carrier alone, or others as indi-
cated in the figures. After 24 h, cells were lysed and normalized
luciferase activities were determined.
U-937, NB4, NB4LR2, and NB4-MR4 cells were electropo-
rated in 250 
 
 
 
l Optimem 1 (GIBCO BRL) with 6 
 
 
 
g pTK-Luc
reporter plasmids, 0.8 
 
 
 
g pRLtk (Promega) per 20 million cells
in a 4-mm thick cuvette by an impulse of 250 V, 950 F. After
transfection, cells were grown in medium containing 10% FBS
for 3 h and then either RA (Sigma-Aldrich) or cAMP (Sigma-
Aldrich), or other reagents as indicated. After 18 h, cells were
lysed and reporter gene activities were determined. Differentia- 
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tion of the APL cell lines NB4, NB4LR2, and NB4MR4 (24)
were assessed using NBT reduction, CD11b expression, and MGG
stains as previously described (17, 25).
 
Quantitative PCR.
 
CD37 gene expression was monitored
with the Light Cycler system (Roche Diagnosis) using SBYR
green fluorescent probe. TBP gene expression was quantified in
the same run as an internal reference. The quantification data
were analyzed using Light Cycler software.
 
Online Supplemental Material.
 
Identity of RAR, PML–
RARA, and RXR DNA–protein complexes is shown in Fig. S1.
Extracts from Cos cells transfected with RAR, RXR, or PML–
RARA were analyzed by band shifting using an optimized DR5
probe. Complexes were super shifted using anti-RARA (A),
anti-PML (P), or anti-RXRA (X) antibodies. The different com-
plexes are indicated by letters. Fig. S1 is available at http://
www.jem.org/cgi/content/full/jem.20032226/DC1.
 
Results
 
Selection of High Affinity Binding DNA Sites for PML–
RARA.
 
The wild-type nuclear receptor RARA and the
PML–RARA fusion protein recognize the same response
element from the 
 
RARB
 
 promoter (6), noted here as
RAREB. Extracts from 
 
PML–RARA
 
-transfected Cos cells
generate two distinct DNA–protein complexes with the
RAREB probe, which were not observed using the ex-
tracts from untransfected cells and were supershifted by ei-
ther anti-RAR or anti-PML antibodies (6). The lowest
band (DIM) corresponds to the PML–RARA homo-
dimer (5, 6, 10) and the upper (OLI) corresponds to a
PML–RARA oligomer (Fig. 1 A; references 6 and 11).
The presence of PML–RARA-DNA complex near the
top of the gel has been reported by others and is due to
the formation of an oligomeric PML–RARA complex
greater than a dimer in size (26 and references therein). To
identify all possible high affinity binding sites for PML–
RARA, we used the selection amplification technique
starting from a pool of DNA sequences containing 25 ran-
dom base pairs. PML–RARA-bound DNA was separated
from free DNA by gel migration. Initially, PML–RARA-
DNA complexes are undetectable. Therefore, we used
RAREB as a marker for migration of the DIM and OLI
PML–RARA complexes (Fig. 1 A). After three rounds
of the selection/amplification, the specific DNA–protein
complexes became visible. As expected, PML–RARA
binding of oligonucleotide increased with additional selec-
tion rounds and the resulting complexes were all super-
shifted by PML antibodies (Fig. 1 A). DNA selected by
PML–RARA binding was subcloned and 172 colonies
were sequenced.
Most of the selected sequences contain an AGGTCA
consensus (Fig. 2 A), which is the common target of type II
nuclear receptors, including RARA. As expected, most
selected sequences (109) contain the consensus repeated
twice. The most spectacular feature of this family of PML–
RARA binding sites is their architecture. Indeed, we found
all possible orientations of the two AGGTCA consensus:
direct, inverted, and everted repeat. Moreover, among
these three orientations, a wide variety of spacing was ob-
served (Fig. 2 B). Clearly, this is very different from known
binding sites for RAR and RXR heterodimers or ho-
modimers and highly unusual for nuclear receptors. Al-
though tolerant to the binding site architecture, PML–
RARA nevertheless has preferred spacing for each repeat
configuration. The number of selected sequences decreases
as follows: DR2 
 
  
 
DR4 
 
  
 
IR0 
 
  
 
DR3 
 
  
 
DR5 
 
  
 
ER8 
 
 
 
DR6, but importantly, spacers up to 12 and 13 were also
selected (Fig. 2). PML-RAR is more selective for inverted
repeat. The number of IR0 sequences is higher than for all
other spacers. Among everted repeats, ER8 is clearly pref-
erential for PML–RARA binding.
Figure 1. Selection of high affinity binding sites for
PML-RARA homodimers. (A) Band shift assays representing
the different steps of the selection/amplification procedure
with Cos cell–expressed PML–RARA protein. The positive
control ( ) is the RAREB response element. V represents
the initial pool of random oligonucleotides and OLI and
DIM point to the two complexes containing PML–RARA
oligomers and dimers, respectively. The fifth (5) and sixth
(6) round of purification derived from the OLI complex
and the sixth (6) round of purification from the DIM com-
plex are shown. Note that the selected sequences are specific
for PML–RARA, as they can be supershifted with anti-PML
antibodies (PML-Ab). (B) Optimized binding site in a
DR5 architecture (DR5) bind PML–RARA and RARA/
RXR with a higher affinity than RAREB ( ). 
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Our selection approach, in addition to defining a core
consensus and spacer lengths, allows the identification of
preferred neighboring bases. We found a strong pressure
for an AA doublet before the AGGTCA core, whatever
the architecture of the PML–RARA binding site. Simi-
larly, the favored first doublet downstream to the core is
CG. The bases neighboring the sites of contact with zinc
fingers often interact with other segments of the protein to
orient it along the DNA (27, 28). In the context of a DR,
this extended consensus influences the composition of the
spacer, allowing us to determine an optimal and extended
PML–RARA binding consensus that defines the internal
bases of the various DR motifs (Fig. 2 C). Interestingly, in
the DR5 architecture, this consensus is strikingly similar to
the natural response element from the 
 
RARB
 
 gene, the
most potent RARE known to date, with the notable ex-
ception of the T within the cores (Fig. 2; reference 23).
Our optimized binding site, in the DR5 architecture, binds
PML/RAR dimers with a 10-fold higher affinity than the
RAREB, and RARA/RXR heterodimers with a fivefold
higher affinity (Fig. 1 B), providing a new tool to probe
endogenous RAR–RXR complexes or to monitor RA re-
sponse in vivo.
 
Analysis of PML–RARA Binding to DRs of Optimized Half
Sites.
 
The effect of mutations within the AGGTCA core
motif was previously studied (26). Therefore, we evaluated
the binding affinity of PML–RARA to a family of se-
quences derived from our optimized consensus in which
DRs of the consensus have spacings varying from 0 to 20.
Similarly to RAREB, two PML–RARA-DNA complexes
were detected in EMSA for all binding sites tested, which
were specifically supershifted using anti-RARA or anti-
PML antibodies and not by anti-RXR antibodies (Fig. 3 A
and unpublished data). Among these sites, the highest affin-
ity was found for DR2 and DR4, consistent with the
greater prevalence of these spacer lengths among selected
Figure 2. Summary of the binding elements identified
by random selection. (A) Nucleotide frequency within
the identified core motif. (B) Summary of the various
architectures and spacings identified among the 109
sequences with two AGGTCA core motifs. (C) Prefer-
ence for specific nucleotides adjacent to the AGGTCA
core in the various architectures. Comparison between
the natural RAREB response element from the RARB
promoter and the optimized DR5 site identified here.
Nonconserved residues are indicated by x. 
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sequences (Fig. 2 B). Strikingly, PML–RARA oligomers
bound DRs with wide spacing (DR 
 
  
 
6; Fig. 3 A), which
were not efficiently recognized by RAR–RXR (unpub-
lished data). Sequences in which one or both of the core
motifs were destroyed bound very weakly (one core mo-
tif  mutated) or not at all (two mutations). Conversely,
when PML–RARA harbored mutations that abolish either
dimerization or DNA binding, no binding was observed
(unpublished data).
 
PML–RARA Is Complexed to RXR in NB4 Cells and
Binds Widely Spaced DRs.
 
PML–RARA may bind RXR
(6) and, in the presence of RXR, the major form of PML–
RARA-containing complex migrated slower than the
DIM complex and can be interpreted as an oligomer con-
taining both PML–RARA and RXR, most likely a tet-
ramer (PML–RARA-RXR)x2 bound to DNA (5, 6, 10,
11), whereas an excess of RXR over PML–RARA gener-
ated a fast migrating RXR homodimer complex with
DNA. Supershift experiments with anti-RAR, anti-RXR,
and anti-PML, as well as use of PML–RARA mutants
(DNA binding, dimerization, RXR binding), were all
consistent with this view (not depicted). The (PML–
RARA-RXR)x1 heterodimer, which was previously de-
tected using the RAREB probe (6), was only detected here
Figure 3. Binding of PML-RAR and PML-
RAR–RXR to direct, inverted, or everted opti-
mized repeats. (A) Extracts of Cos cells transfected
with PML–RARA were analyzed by band shifting
using as probes DRs separated with the indicated
number of bases, as well as palindromes (inverted or
everted repeats, IR0 and ER8). On the right, controls
were the RAREB probe ( ), untransfected cells
(Ø), or a DR5 where one hexamer was mutated
( ). Ratio of bound/nonbound probe is shown
above. Bold line, OLI complex; thin line, DIM
complex. (B) Same as A, using extracts of Cos cells
transfected with PML–RARA and RXRA. Note
that a single complex corresponding to PML–
RARA-RXRA oligomers (arrow) is observed with
most probes. A rapidly migrating complex (arrow-
head) is observed with DR1 and DR6 corresponds
to RXRA homodimers.
Figure 4. Identification of PML–RARA-
RXR tetramers in APL cells. Binding sites
ER8, DR8, and DR2 were presented to increas-
ing amounts of the NB4 nuclear extracts. The
gel mobility of the complexes was compared
with extracts of Cos cells transfected with
RXRA (RXR), PML–RARA (P/R), or both
(P/R RXR). Identity of DNA–protein com-
plexes was tested by supershifting with anti-
RARA ( -A), anti-PML ( -P), and anti-RXR
( -X) antibodies. The arrow points to the
PML–RARA-RXR oligomers, OLI and DIM,
and to the PML–RARA-only complexes. 
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as the transitory product in RXR titration experiments
(not depicted). The binding selectivity of RXR homo-
dimer obtained with DR1/DR20 elements confirmed its
preferential binding to DR1 and DR6 (1). In contrast,
PML–RARA-RXR oligomers bound DNA with much
less restrictions. DRs with spacing varying from 1 to 20, as
well as both IR or ER palindromes, were all efficiently
bound (Fig. 3 B). The binding preferences were somehow
distinct from those of PML–RARA homodimers. As ex-
pected, for DRs with small spacing (DR 
 
  
 
6), the affinity
profile of PML–RARA-RXR oligomers is close to that of
the normal RAR–RXR heterodimers, with a greater affin-
ity for DR1 and DR5 than for DR4 (Fig. 3). Yet, in sharp
contrast to RAR–RXR, PML–RARA-RXR oligomers
bound DR with very long spacing (DR6–20).
The availability of very high affinity binding sites for
PML–RARA allowed us to detect endogenous PML–
RARA in leukemic cells by EMSA. Using several methods
to prepare nuclear extracts, we constantly found PML–
RARA as PML–RARA-RXR oligomers and, impor-
tantly, we could never detect PML–RARA homodimers
although the probes used here (DR8, DR2, and ER8)
were optimized for homodimer binding (Fig. 4 A). This
specific DNA–protein complex involves the protein moi-
eties containing PML, RAR, and RXR as demonstrated
by supershifting (Fig. 4 B). We constantly found that the
PML–RARA-RXR oligomers derived from NB4 cells
had a slightly retarded mobility when compared with the
ones derived from transfected Cos cells. This likely reflects
the poor efficiency of posttranslational modifications such
as phosphorylation or sumolation in transfected cells (5,
29). This experiment very strongly suggests that in APL,
the predominant form of the fusion protein is a PML–
RARA-RXR oligomer.
 
Identification of PML–RARA-specific Transcriptional Re-
sponse Elements.
 
To test if these selected DNA sequences
are not only effective binding sites, but also functional re-
sponse elements, we inserted a single copy of the DR with
a 1–16-bp spacer upstream to a 
 
TK
 
 minimal promoter
fused with a luciferase reporter cDNA (pTK luciferase vec-
tor). In the absence of 
 
PML–RARA
 
 expression in the Cos
cells, no significant change in reporter gene activity was
found upon treatment with RA, except with DR-5 and
DR-2 inserts that are well-known to bind endogenous
RAR–RXR heterodimers (Fig. 5 A). When a 
 
PML–
RARA
 
 expression vector was cotransfected with the re-
porters in the absence of RA, a significant transcription re-
pression was observed from all reporters that contained
bindings sites (Fig. 5 B). In contrast, when PML–RARA-
expressing cells were treated with RA, an induction of
luciferase transcription was observed for many repeats, in-
cluding DR8, DR12, IR0, and ER8 (Fig. 5 A). Compar-
ing the level of reporter expression in the absence of PML–
RARA, we found that in most cases, RA derepressed,
rather than activated (DR5 and DR6), but for DR8
elements, some PML–RARA-dependent activation was
observed (Fig. 5 B). Similar results were obtained when
 
PML–RARA
 
 was cotransfected along with an expression
vector for RXR (unpublished data).
We then turned to a system that more closely reflects the
situation of leukemic cells by electroporating these reporters
in NB4 cells, which express levels of PML–RARA, RAR,
and RXR similar to those present in APL blasts. A very
strong transcriptional activation/derepression was observed
after RA treatment for all reporters tested, except DR1 and
DR16. In particular, DR4, DR6, and DR8 motifs con-
ferred a major response to RA (
 
 
 
30-fold; Fig. 5 C). To ad-
Figure 5. Identification of PML–RARA-specific response elements.
(A) DRs separated with spacers of the indicated length, as well as ER8
and IR0, were inserted in a TK-Luc vector and tested for induction in
the presence of RA. Values reported are averaged from three independent
experiments in Cos cells. Shaded bars denote the induction in the presence
of cotransfected PML–RARA expression vector, striped bars represent
induction by endogenous RARA–RXR complexes. (B) PML–RARA
induces repression on several PML–RARA binding sites. Note that RA only
relieves repression on DR5 and DR6, but activates on DR8. (C) Reporter
constructs were electroporated in NB4 APL cells that express endogenous
RARA and PML–RARA proteins. (D) As in C, except that non-APL
U937 cells that express RARA, but not PML–RARA, were used. 
Kamashev et al.
 
1169
dress the specificity of response in a cell line that does not
express PML–RARA, we studied hematopoietic U937 cells.
As expected, we only found a significant RA response with
the RAR–RXR targets DR2 and DR5 (Fig. 5 D). We have
thus identified a subset of response elements that confer re-
sponse to PML–RARA, but not RARA. Among these,
some are specific for other nuclear receptors (DR4, thyroid
hormone receptor), whereas others (DR8, DR10, etc.) have
never been identified as nuclear receptor binding sites.
To demonstrate in an in vivo setting that these elements
are specific for PML–RARA, we performed a search for
such elements in the promoters of known human genes in
the Eukaryotic Promoter Database (http://www.epd.isb-sib.
ch). 13 genes contain DR7-DR16 elements within their
proximal promoter and do not contain DR 
 
  
 
6. Expression
of four of these genes containing large DRs was monitored
by quantitative PCR during a time course of RA response
in NB4 or HL60 cells (CD37, COX8, RAD51C, and
PDHA1). CD37 (DR11) was induced fivefold by RA after
12 h in APL, but not in HL60 acute myeloid leukemia cells
that differentiate in response to RA, but do not express
PML–RARA (Fig. 6). Strikingly, comparing the baseline
CD37 gene expression in NB4 and HL60 cells, we found
that it was expressed at much higher levels in HL60 cells
(20-fold). Hence, this gene that harbors a PML–RARA-
specific binding site within its promoters is repressed in
NB4 compared with HL60 cells and partially derepressed
upon RA exposure (Fig. 6). The three others genes were
not induced by RA. Hence, the presence of the PML–
RARA-specific response elements is not sufficient for RA
induction in APL cells, possibly reflecting low accessibility
of these binding sites in vivo due to chromatin structure.
 
cAMP Desubordinates RXR Transactivation in Either PML–
RARA/RXR or RAR–RXR Complexes.
 
cAMP greatly
enhances arsenic- or RA-triggered differentiation ex vivo or
in vivo (17, 30–32), and triggers APL cell differentiation in
vivo (17). In NB4 cells, cAMP administration modestly ac-
tivated the DR5 reporter (1.5–2-fold), but did not affect
DR8 or DR10 (unpublished data). Although additive ef-
fects were noted on DR5 reporters, a sharp synergy (up to
sixfold) between cAMP and RA was noted on PML–
RARA-specific DR8 and DR10 (Fig. 7 A), strongly sug-
gesting that cAMP potentiation of RA-induced differentia-
tion results from a direct enhancement of the transcription
of primary 
 
PML–RARA
 
 target genes. A dose response anal-
ysis of RA-triggered PML–RARA-dependent activation
demonstrated that activation plateaued above 10
 
 
 
8 
 
M (Fig. 7
B) and that cAMP greatly enhanced the maximal level of
activation and was sensitized to the effects of RA. Similarly,
Figure 6. Identification of natural PML–RARA-specific RA targets in
APL cells. CD37 mRNA expression relative to TBP mRNA in NB4 cells
(solid lines) or HL60 (dotted line) were monitored using quantitative
RT-PCR after exposure to 1  M RA for the indicated time.
Figure 7. Synergistic transcriptional activation by
RA and cAMP. (A) NB4 cells were electroporated
with the indicated reporters and treated with the follow-
ing retinoids, as indicated: RA, BMS753 (RARA ),
or BMS649 (RXR ), in the presence or absence of
160  M cAMP for 18 h. (B) Dose response of RA-
triggered activation on PML–RARA-specific reporter
DR8 in NB4 cells, in the presence or absence of
cAMP. (C) Same as in A, except that NB4LR2 cells
were tested. (D) Same as in A and C, except that U937
cells were tested. 
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combining forskolin and phosphodiesterase inhibitors also
enhanced RA-triggered transcription (unpublished data).
Our demonstration that in APL cells RXR is bound to
PML–RARA and that cAMP enhances transcriptional acti-
vation by this complex led us to reevaluate the existence of
the PML–RARA-independent RXR/cAMP differentia-
tion pathway by using RARA- and RXR-specific ligands
(19). As expected, RARA-specific agonist strongly acti-
vated PML–RARA-specific reporters and response was in-
creased by cAMP. Although neither RXR-specific agonists
nor cAMP induced significant activation on DR5-, DR6-,
or DR8-containing reporters, their association induced a
robust sevenfold increase in luciferase activity (Fig. 7 A),
suggesting that cAMP desubordinates RXR and allows it
to become a transcriptional activator on the DR8 reporter,
which binds PML–RARA. Similar results were obtained
with BMS 749, a compound with both RXR agonist and
RARA antagonist activities (unpublished data). As a con-
trol, we used NB4LR2 APL cells, which harbor a frame-
shift mutation in the 
 
RARA
 
 moiety of 
 
PML–RARA
 
 that
deletes the RA binding pocket (33). PML–RARA-depen-
dent activation was observed exclusively by combining a
rexinoid and cAMP (Fig. 7 C), but not with rexinoids
alone nor RARA agonists in the presence or absence of
cAMP. Altogether, these experiments demonstrate that
cAMP allows RXR to enhance PML–RARA-dependent
transcription, resulting in an induction of differentiation.
To verify that this is also the case in the context of the
wild-type RAR–RXR heterodimers, we tested the ability
of RARA agonists or rexinoids to activate transcription
from a DR5-containing reporter in U937 cells. As ex-
pected, RARA agonists strongly activated transcription and
cAMP further enhanced response, whereas cAMP was
absolutely required for rexinoid-mediated transactivation
(Fig. 7 D). Hence, cAMP also desubordonnates RXR in
the context of the endogenous RXR/RAR heterodimers.
 
cAMP Can Restore RA Sensitivity and PML–RARA Tran-
scription in an RA-resistant NB4 Clone.
 
In NB4MR4 APL
cells, a point mutation in the E domain of PML–RARA
impairs RA binding, resulting in RA resistance (34). Yet,
in studying an animal model of RA-resistant APL in which
the PML–RARA transgene harbors this same mutation
(35), we found that the cAMP/RA association triggered
terminal differentiation in vivo (17). Testing the hypothesis
that cAMP may also circumvent RA resistance in the
NB4MR4 cell line, we found that cAMP indeed restored
RA-triggered differentiation (Fig. 8). When we probed
PML–RARA signaling in these cells using DR5 or
DR8, neither RA nor cAMP induced luciferase expres-
sion, but the combination of these two drugs triggered a
major transcriptional activation (Fig. 8 and not depicted).
Hence, RA/cAMP transcriptional activation through PML–
RARA strictly parallels APL cell differentiation ex vivo
and in vivo.
Figure 8. cAMP restores RA-
triggered differentiation in NB4MR4
cells. NBT reduction (A), CD11b
expression (B), or May Grunwald
Giemsa staining (C) were measured
after a 4-d treatment with the indi-
cated drug (10 6 M) and/or 200  M
cAMP in NB4 or NB4MR4 cells, as
indicated. (D) Transcriptional acti-
vation on a DR8 reporter upon
electroporation in NB4MR4 cells
and treatment with the indicated
drugs. Note that activation of PML–
RARA-dependent transcription mir-
rors differentiation induction. 
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That cAMP restored RA response in NB4MR4 cells was
surprising. RA might be isomerized into 9-cis-RA, a com-
pound that efficiently binds and activates RXR. Thus, we
used RARA- and RXR-specific ligands and assessed both
differentiation and transcriptional activation. As expected,
neither differentiation nor transactivation was found with
either compound alone (Fig. 8). In contrast, in the presence
of cAMP, either RARA- or RXR-specific agonists in-
duced both transcriptional activation of PML/RAR-spe-
cific reporters and differentiation. Although this was
expected for the rexinoid, reporter activation and differen-
tiation induction by the RARA agonist/cAMP association
was surprising and clearly distinguishes NB4LR2 from
NB4MR4 cells. RA-triggered NB4MR4 differentiation
was impaired by the RARA antagonists BMS 493 and
BMS 009, or the protein kinase A inhibitor H89 (unpub-
lished data). These observations imply that transcriptional
activation and differentiation induction in these cells ex
vivo (Fig. 8) or in vivo (17) are mediated by the RARA
moiety of the fusion, likely through a change in its RA
binding properties triggered by cAMP signaling.
 
Discussion
 
High affinity PML–RARA binding sites consist of a
highly conserved consensus for RARA arranged in a vari-
ety of spatial arrangements, extending previous reports that
PML–RARA may bind DR1–DR5 response elements (5,
6, 10). This extended consensus (A-AGGTCA-C) is likely
the best binding site, not only for PML–RARA, but also
for RARA, especially as DR2 and DR5. Our observations
imply that PML-induced dimerization, remote from the
DNA binding domains, allows the two RARA moieties
of PML–RARA to bind very distant monomeric DNA
sites, even if contacts between them are spatially impossi-
ble. The spectrum of response elements for PML–RARA
and PML–RARA-RXR (DR1–DR16) is much broader
than one for the wild-type RAR–RXR (DR1, DR2, and
DR5). Hence, the fusion protein is likely to repress a very
large number of genes including, but not limited to, all
those controlled by all type II nuclear receptors. Accord-
ingly in APL cells, RA activates a much larger number of
genes than it does in non-APL leukemias (13). This
broader spectrum of genes regulated by PML–RARA (or
RA) identifies a major gain of function of this oncogene.
In vitro DNA binding assays show that PML–RARA
may interact with RXR, yielding PML–RARA-RXR oli-
gomers. The presence of RXR changes the DNA bind-
ing preferences of PML–RARA. Oligomers, but not ho-
modimers, recognizes DR1 well, binds DR5 more avidly
than DR4, and binds IR0 stronger than ER8. In NB4 cells,
RA stimulation of DR1 in NB4 is modest, likely reflecting
the purely repressive function of RAR–RXR on DR1 ele-
ments (36), and RA stimulation of DR5 reporters is stron-
ger than DR4, all suggestive for the predominance of PML–
RARA-RXR oligomers. The DNA binding experiments
with NB4 nuclear extracts directly show that with the stoi-
chiometry of PML–RARA and RXR within these cells,
PML–RARA is entirely complexed with RXR. Yet, the
most demonstrative experiment for the presence of endoge-
nous PML–RARA-RXR oligomers is the strong transcrip-
tional response of PML–RARA-specific reporters (DR8
and DR10) to the rexinoid/cAMP treatment. PML–
RARA homodimers and PML–RARA-RXR oligomers
have very different mechanisms of protein–DNA interac-
tions. Although for homodimers, each DNA recognition
surfaces binds a single hexamer, oligomers harbor at least
four DNA recognition surfaces of which two only interact
with DNA. Two adjacent or distant RARA or RXR moi-
eties become tethered onto DNA without directly binding
it. On the targets on the RAR–RXR heterodimer (DR1,
DR2, and DR5), binding is likely to be dependent on
RARA and its bound RXR. On other small DRs (DR3
and DR4) as well as large ones (
 
 
 
6) binding is likely to in-
volve the two RARAs from each of the two fusions or the
bound RXRs. DNA binding has been implicated in RARs
degradation (15, 37), possibly through a shift in RAR–
RXR conformation, which may not occur in the context
of oligomers. In any case, the existence of PML–RARA-
RXR oligomers in APL cells does not favor the previously
proposed model in which transformation is only accounted
by an enhanced binding affinity of corepressors on PML–
RARA homodimers (8, 9), as RXRs are most likely to shift
the RA-triggered corepressor dissociation curve toward that
of the normal RARA–RXR complexes.
Some authors found that like RARA, PML–RARA is
an RA-dependent activator (38–40), whereas others show
that even in the presence of RA, PML–RARA remains a
repressor (10, 41). Both our transient transfection data us-
ing PML–RARA-specific reporters and repression of the
natural PML–RARA-specific target CD37 in APL com-
pared with HL60 cells, strongly suggest that the fusion re-
mains a potent repressor even in the presence of RA. Sim-
ilarly, recent studies in 
 
Xenopus
 
 oocytes (42) have led
support to the observations with the 
 
RARB
 
 gene that the
fusion is a pure repressor, even in the presence of RA
(41). cAMP dramatically enhances transcriptional response
to RA or RARA-specific agonists on both RARA-
and PML–RARA-specific elements, providing a plausible
mechanism for cAMP-facilitated RA-triggered APL cell
differentiation (30). Here we also show that cAMP unrav-
els the ability of rexinoid to activate either RARA or
PML–RARA-specific reporters, identifying the first physi-
ological signal that mediates RXR desubordination. Previ-
ously, RXR desubordination had only been achieved in
artificial settings such as a combination of RARA antago-
nist and RXR agonists (43) or overexpression of coactiva-
tors (3). cAMP greatly enhances expression of the PGC-1
coactivator (44, 45) and recent reports have pointed to dy-
namic equilibrium between corepressor, coactivators, and
RA-bound conformations of RARA (46), which may ex-
plain our findings. Alternatively, as in F9 cells (18), cAMP
might also facilitate RA- and rexinoid-triggered differenti-
ation through direct phosphorylation of the RARA moi- 
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ety of PML–RARA, which may directly or indirectly alter
the binding efficiency of corepressors and coactivators.
This last hypothesis is favored by the paradoxical res-
toration of RA and RARA agonist response by cAMP
in NB4MR4 cells, which suggests that cAMP-triggered
RARA phosphorylation induces a conformation change
that restores its ability to bind RA. Whatever the mecha-
nism(s) involved, that cAMP strongly activates PML–
RARA targets, identifies this clinically relevant agent as yet
another oncogene-targeted therapy.
Using a variety of drugs, mutant cell lines, and PML–
RARA-specific reporters, we directly show a very strict
parallelism between transcriptional activation of PML–
RARA targets and NB4 differentiation. The complete
reversal of RA resistance by cAMP in NB4MR4 cells cou-
pled to restoration of PML–RARA-dependent transactiva-
tion, also stresses the central role of the fusion over the
normal RARA receptor in differentiation induction. Simi-
larly, that the rexinoid/cAMP combination activates tran-
scription from PML–RARA-specific reporters, strongly
suggests that the previously described PML–RARA-inde-
pendent cAMP/rexinoid differentiation pathway (19) in
fact also triggers differentiation through PML–RARA tar-
gets, with cAMP desubordinating PML–RARA-bound
RXR. Previous studies had outlined distinct gene activa-
tion profiles in RA- or cAMP/rexinoid-treated NB4 cells
(19), and experiments based on differentiation kinetics of
variant NB4 cells had suggested that cAMP acts down-
stream of RA-induced differentiation priming (32). Yet,
our data unambiguously demonstrates an upstream effect of
cAMP on PML–RARA signaling, which does not exclude
a later cooperation with cAMP downstream targets.
Monitoring PML–RARA targets through transient
transfections or quantitative PCR demonstrates that they
are activated/derepressed by a number of differentiating
agents. Yet, arsenic trioxide rapidly degrades PML–RARA
and a sharp RA/arsenic synergism was observed in both
mice (47, 48) and patients, which is inconsistent with an
absolute dependence of differentiation for PML–RARA-
triggered gene activation. In contrast, this last observation
favors a model in which differentiation is only dependent
on derepression (13). Altogether, our data show that PML–
RARA-RXR oligomers silence a wide range of nuclear
receptor target genes and that all known relevant differenti-
ating agents RA, arsenic, cAMP, HDAC inhibitors, and
rexinoids relieve this repression through various molecular
mechanisms that nevertheless, all target the PML–RARA-
RXR–HDAC complexes, allowing spontaneous differenti-
ation of the leukemic blasts.
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